PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
H. cordata-derived nanoparticles and polysaccharides reduced weight loss, preserved mucosal integrity, and inhibited pro-inflammatory cytokines [PMID:41205527, 36549805, 39742094]
Homogeneous polysaccharides (HCPM) improved survival and reduced lung injury in H1N1 and MRSA coinfection models [PMID:40654358, 40973292]
2-Undecanone reduced inflammatory cell infiltration and levels of IL-4, IL-5, IL-13, and IgE in BALF [PMID:36480816]
Polysaccharides (HCP) reduced epidermal thickness, skin lesions, and mast cell infiltration [PMID:40393586]
Extracellular vesicle-like particles suppressed ferroptosis via miR159a targeting ACSL4 [PMID:40890801]
Safety & adverse effects
Pregnancy & lactation
Evidence summary
PubMed sources
- 1.PMID: 39742094 (2024) — Houttuynia cordata-Derived Exosome-Like Nanoparticles Mitigate Colitis in Mice via Inhibition of the NLRP3 Signaling Pathway and Modulation of the Gut Microbiota. · International journal of nanomedicine
- 2.PMID: 40050867 (2025) — Antiviral treatment for viral pneumonia: current drugs and natural compounds. · Virology journal
- 3.PMID: 37901360 (2023) — Identifying the Potential of miRNAs in Houttuynia cordata-Derived Exosome-Like Nanoparticles Against Respiratory RNA Viruses. · International journal of nanomedicine
- 4.PMID: 40654358 (2025) — An anti-complement homogeneous polysaccharide from Houttuynia cordata ameliorates acute pneumonia with H1N1 and MRSA coinfection through rectifying Treg/Th17 imbalance in the gut-lung axis and NLRP3 inflammasome activation. · Acta pharmaceutica Sinica. B
- 5.PMID: 34539401